187 related articles for article (PubMed ID: 31160694)
1. Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications.
Kumar A; Kumari N; Sharma U; Ram S; Singh SK; Kakkar N; Kaushal K; Prasad R
Sci Rep; 2019 Jun; 9(1):8189. PubMed ID: 31160694
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.
Kumar A; Kumari N; Nallabelli N; Sharma U; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2020 May; 739():144498. PubMed ID: 32097694
[TBL] [Abstract][Full Text] [Related]
3. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Pires-Luís AS; Vieira-Coimbra M; Vieira FQ; Costa-Pinheiro P; Silva-Santos R; Dias PC; Antunes L; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2015; 10(11):1033-43. PubMed ID: 26488939
[TBL] [Abstract][Full Text] [Related]
4. SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.
Ferreira MJ; Pires-Luís AS; Vieira-Coimbra M; Costa-Pinheiro P; Antunes L; Dias PC; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2017; 12(12):1057-1064. PubMed ID: 29099276
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma.
Ellinger J; Kahl P; Mertens C; Rogenhofer S; Hauser S; Hartmann W; Bastian PJ; Büttner R; Müller SC; von Ruecker A
Int J Cancer; 2010 Nov; 127(10):2360-6. PubMed ID: 20162570
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Kumar A; Kumari N; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2018 Oct; 674():31-36. PubMed ID: 29944950
[TBL] [Abstract][Full Text] [Related]
7. Expression and significance of histone H3K27 demethylases in renal cell carcinoma.
Shen Y; Guo X; Wang Y; Qiu W; Chang Y; Zhang A; Duan X
BMC Cancer; 2012 Oct; 12():470. PubMed ID: 23057811
[TBL] [Abstract][Full Text] [Related]
8. Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer.
Hong Z; Li H; Li L; Wang W; Xu T
Cancer Biomark; 2017; 18(2):125-131. PubMed ID: 27983522
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
10. The molecular landscape of histone lysine methyltransferases and demethylases in non-small cell lung cancer.
Li J; Tao X; Shen J; Liu L; Zhao Q; Ma Y; Tao Z; Zhang Y; Ding B; Xiao Z
Int J Med Sci; 2019; 16(7):922-930. PubMed ID: 31341405
[No Abstract] [Full Text] [Related]
11. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Rondinelli B; Rosano D; Antonini E; Frenquelli M; Montanini L; Huang D; Segalla S; Yoshihara K; Amin SB; Lazarevic D; The BT; Verhaak RG; Futreal PA; Di Croce L; Chin L; Cittaro D; Tonon G
J Clin Invest; 2015 Dec; 125(12):4625-37. PubMed ID: 26551685
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
14. In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
Kumar A; Nallabelli N; Sharma U; Kumari N; Singh SK; Kakkar N; Prasad R
Mol Biol Rep; 2020 Sep; 47(9):7273-7276. PubMed ID: 32754863
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Katz TA; Vasilatos SN; Harrington E; Oesterreich S; Davidson NE; Huang Y
Breast Cancer Res Treat; 2014 Jul; 146(1):99-108. PubMed ID: 24924415
[TBL] [Abstract][Full Text] [Related]
16. Histone modifications: implications in renal cell carcinoma.
Ramakrishnan S; Ellis L; Pili R
Epigenomics; 2013 Aug; 5(4):453-62. PubMed ID: 23895657
[TBL] [Abstract][Full Text] [Related]
17. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma.
Rogenhofer S; Kahl P; Mertens C; Hauser S; Hartmann W; Büttner R; Müller SC; von Ruecker A; Ellinger J
BJU Int; 2012 Feb; 109(3):459-65. PubMed ID: 21810159
[TBL] [Abstract][Full Text] [Related]
18. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
[TBL] [Abstract][Full Text] [Related]
19. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
20. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
